NCT06855589View on ClinicalTrials.gov

Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2033

Study Completion Date

March 31, 2034

Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
DRUG

6 months of Eligard

Total of two 3-month injections of a LHRH agonist for total duration of 6 months

DRUG

12 months of Eligard

Total of four 3-month injections of a LHRH agonist for total duration of 12 months

RADIATION

prostate SBRT or prostate brachytherapy with radiation therapy

Patients may receive prostate stereotactic body radiation therapy or a combination of high-dose rate brachytherapy with radiation therapy; as per the treating physician's preference

Trial Locations (5)

J8P7H2

Hôpital de Gatineau, Gatineau

J4V2H1

Hôpital Charles LeMoyne, Longueuil

H1T2M4

Hôpital Maisonneuve-Rosemont, Montreal

H3T 1E2

Jewish General Hospital, Montreal

J1H5H3

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

All Listed Sponsors
lead

Charles LeMoyne Hospital

OTHER